Effect of Cerebrolysin on the Blood Brain Barrier in Patients With Diabetes and Ischemic Stroke

Inclusion Criteria:

1. Age 18 - 80 years.
2. Clinical and imaging criteria for ischemic stroke of the middle cerebral artery.
3. Acute non-lacunar cerebral infarction.
4. Cerebral infarction with a score on the NIH scale between 5 and 20 points.
5. Patient with a previous diagnosis of type 2 diabetes mellitus, regardless of the formof diagnosis, time of evolution, previous or current treatment, adherence or not totreatment, presence or absence of microvascular and/or macrovascular complications.
6. mRs ≤ 1 before the qualifying stroke (functionally independent for all activities ofdaily living).
7. The patient and/or legal representative or direct family member has signed theinformed consent form.

Exclusion Criteria:

1. Advanced disease or terminal with life expectancy < 6 months.
2. • Over 80 years old
3. Lacunar infarction or small vessel disease.
4. Pre-existing medical, neurological, or psychiatric disease that would confoundneurological or functional evaluations (eg, Alzheimer's disease, vascular dementia,Parkinson's disease, demyelinating disease, encephalopathy of any cause, history ofsignificant alcohol or drug abuse).
5. Pregnancy or lactation.
6. Acute or chronic renal failure with creatinine clearance <30 mL/min.
7. Allergy or any condition that represents a contraindication for the administration ofCerebrolysin.
8. Treatment with another investigational drug within the past 30 days that may interferewith the study drug.